Is BIIB a good stock to buy?
Biogen Inc. · end-of-day data as of Nov 13, 2026
- ConsensusBuy · 36
- Trendbullish
- MAs4 of 4
- Sector▲ +15.9%
- Earnings in84d
- P/E108.3x
- RSI59
- Support-10.6%
- Off 52w high-2.9%
- Volume0.8x
- Bollingerupper half
- News0.00
- PT$254.56 +0.5%
- 52w range$160–$261
- ATR+3.1%
- Off ATH-47.2%
- InsidersNone in 90d
- P/E vs own+148.5%
- P/E vs sector+236.2%
- MACD-0.62
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Biogen a good stock to buy?
Biogen is strong on 1 of the 4 questions about the business; weak on demand and economics. The price is high: 108.3 times its earnings, above its 3-year median of 19.8 (Nov 13, 2026). pretickt does not say whether to buy or sell.
BIIB competitors
pretickt analysis+3%its sales in 12 months, on a year before
Biogen's sales grew 3% in the 12 months to Sep 30, 2026, faster than Pfizer (+1%), slower than Amgen (+8%), Gilead (+7%) and Bristol-Myers Squibb (+4%).
BIIB sales by business revenue by segment
42%of its sales from MS Product RevenuesMS Product Revenues brought Biogen 42% of its sales in fiscal 2025; TYSABRI product 17%.
BIIB earnings vs estimates
8 of 8quarters above the analysts' estimateBiogen beat the analysts' profit estimate in each of its last 8 quarters, the latest on Oct 28, 2026.
BIIB insider selling
-$905Ksold, net, by its executives in 12 monthsBiogen's executives and directors sold a net $905K of shares in the 12 months to Nov 13, 2026 ($905K sold, $585 bought).
BIIB number of employees
-1%fewer people in a yearBiogen had 7,500 employees at the end of fiscal 2025, 1% fewer than a year before.
BIIB CEO pay
$23.65Mfor fiscal 2025, 78% of it in stock and optionsBiogen paid its CEO $23.65M for fiscal 2025, 78% of it in stock and options.
BIIB financial health Altman Z-score
3.1Altman Z-score, safe above 3Biogen's Altman Z-score is 3.1 (Nov 13, 2026), above 3, where the safe zone starts.
BIIB biggest customers
44%of sales from its 2 biggest customersTwo customers, unnamed in Biogen's 10-K, made 44% of its sales in fiscal 2025.
BIIB in past recessions
pretickt analysis-6%its sales in the worst oneBiogen's sales fell in 1 of the last 2 US recessions, by as much as 6% in fiscal 2020.
BIIB price vs profit P/E ratio
108.3×a year's earningsBiogen's P/E ratio is 108.3 (Nov 13, 2026), above its 3-year median of 19.8.
BIIB price vs competitors
pretickt analysis108.3×a year's earnings, against its competitorsInvestors pay 108.3 times Biogen's earnings (Nov 13, 2026), more than for Pfizer (41.5), Amgen (27.0) or Bristol-Myers Squibb (14.1).
BIIB analysts' target price target
0%to their average targetAnalysts' average price target for Biogen is $255, 0% above the Nov 13, 2026 close of $253.40.
BIIB analyst ratings, 90 days
pretickt analysisJP Morganupgrade Argus Researchupgrade
In the 90 days to Nov 13, 2026, JP Morgan and Argus Research upgraded Biogen.
What is Biogen's P/E ratio?
Biogen's P/E ratio is 108.3 (Nov 13, 2026), above its 3-year median of 19.8. Investors pay 108.3 times Biogen's earnings (Nov 13, 2026), more than for Pfizer (41.5), Amgen (27.0) or Bristol-Myers Squibb (14.1).
Who are Biogen's biggest competitors?
pretickt compares Biogen with Bristol-Myers Squibb, Pfizer, Gilead and Amgen. Biogen's sales grew 3% in the 12 months to Sep 30, 2026, faster than Pfizer (+1%), slower than Amgen (+8%), Gilead (+7%) and Bristol-Myers Squibb (+4%).
Are insiders selling Biogen stock?
Biogen's executives and directors sold a net $905K of shares in the 12 months to Nov 13, 2026 ($905K sold, $585 bought).
How does Biogen make money?
MS Product Revenues brought Biogen 42% of its sales in fiscal 2025; TYSABRI product 17%.
How many employees does Biogen have?
Biogen had 7,500 employees at the end of fiscal 2025, 1% fewer than a year before.
Who are Biogen's biggest customers?
Two customers, unnamed in Biogen's 10-K, made 44% of its sales in fiscal 2025.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.